NAD-dependent deacetylase sirtuin 2 is anenzyme that in humans is encoded by theSIRT2gene.[5][6][7] SIRT2 is anNAD+ (nicotinamide adenine dinucleotide)-dependent deacetylase. Studies of this protein have often been divergent, highlighting the dependence of pleiotropic effects of SIRT2 on cellular context. The natural polyphenolresveratrol is known to exert opposite actions on neural cells according to their normal or cancerous status.[8] Similar to othersirtuin family members, SIRT2 displays a ubiquitous distribution. SIRT2 is expressed in a wide range of tissues and organs and has been detected particularly in metabolically relevant tissues, including thebrain,muscle,liver,testes,pancreas,kidney, andadipose tissue of mice. Of note, SIRT2 expression is much higher in the brain than all other organs studied, particularly in thecortex,striatum,hippocampus, andspinal cord.[9]
Studies suggest that the human sirtuins may function as intracellular regulatory proteins with mono-ADP-ribosyltransferase activity.[7] Cytosolic functions of SIRT2 include the regulation ofmicrotubuleacetylation, control ofmyelination in thecentral andperipheral nervous system[citation needed] and gluconeogenesis.[10] There is growing evidence for additional functions of SIRT2 in thenucleus. During theG2/M transition, nuclear SIRT2 is responsible for globaldeacetylation ofH4K16, facilitatingH4K20methylation and subsequentchromatin compaction.[11] In response toDNA damage, SIRT2 was also found to deacetylateH3K56 in vivo.[12] Finally, SIRT2 negatively regulates theacetyltransferase activity of the transcriptional co-activator p300 via deacetylation of an automodification loop within its catalytic domain.[13]
Human SIRT2 gene has 18exons resides onchromosome 19 at q13.[7] ForSIRT2, four different human splice variants are deposited in the GenBank sequence database.[14]
SIRT2 gene encodes a member of thesirtuin family of proteins, homologs to the yeast Sir2 protein. Members of the sirtuin family are characterized by a sirtuin core domain and grouped into four classes. The protein encoded by this gene is included in class I of the sirtuin family. Several transcript variants are resulted from alternative splicing of this gene.[7] Only transcript variants 1 and 2 have confirmed protein products of physiological relevance. Aleucine-rich nuclear export signal (NES) within theN-terminal region of these two isoforms is identified.[14] Since deletion of the NES led to nucleocytoplasmic distribution, it is suggested to mediate their cytosolic localization.[15]
(S)-2-Pentyl-6-chloro,8-bromo-chroman-4-one: IC50 of 1.5 μM, highly selective over SIRT2 andSIRT3[16]
3′-Phenethyloxy-2-anilinobenzamide (33i): IC50 of 0.57 μM[17]
AGK2 (C23H13Cl2N3O2; 2-cyano-3-[5-(2,5-dichlorophenyl)-2-furanyl]-N-5-quinolinyl-2-propenamide) is a potent, cell-permeable, selective SIRT2 inhibitor that minimally affects both SIRT1 and SIRT3[18]
SIRT2 suppresses inflammatory responses in mice throughp65 deacetylation and inhibition ofNF-κB activity.[19] SIRT2 is responsible for the deacetylation and activation ofG6PD, stimulatingpentose phosphate pathway to supply cytosolicNADPH to counteract oxidative damage and protect mouseerythrocytes.[20]
Several studies in cell and invertebrate models ofParkinson's disease (PD) andHuntington's disease (HD) suggested potential neuroprotective effects of SIRT2 inhibition, in striking contrast with other sirtuin family members.[21][22] In addition, recent evidence shows that inhibition of SIRT2 protects againstMPTP-induced neuronal loss in vivo.[23]
Several SIRT2deacetylation targets play important roles in metabolichomeostasis. SIRT2 inhibits adipogenesis by deacetylatingFOXO1 and thus may protect againstinsulin resistance. SIRT2 sensitizes cells to the action of insulin by physically interacting with and activatingAkt and downstream targets. SIRT2 mediatesmitochondrial biogenesis by deacetylatingPGC-1α, upregulatesantioxidant enzyme expression by deacetylatingFOXO3a, and thereby reducesROS levels. Also, Sirt2 can reactivate the inactive G6PD by removing the acetyaltion at K403[24].
Although preferentially cytosolic, SIRT2 transiently shuttles to thenucleus during the G2/M transition of thecell cycle, where it has a strong preference forhistone H4lysine 16 (H4K16ac),[25] thereby regulating chromosomal condensation duringmitosis.[26] During the cell cycle, SIRT2 associates with several mitotic structures including thecentrosome,mitotic spindle, andmidbody, presumably to ensure normalcell division.[15] Finally, cells with SIRT2 overexpression exhibit marked prolongation of the cell cycle.[27]
Mounting evidence implies a role for SIRT2 intumorigenesis. SIRT2 may suppress or promote tumor growth in a context-dependent manner. SIRT2 has been proposed to act as a tumor suppressor by preventing chromosomal instability during mitosis.[28] SIRT2-specific inhibitors exhibits broad anticancer activity.[29][30]
^"Human PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:".National Center for Biotechnology Information, U.S. National Library of Medicine.
^Afshar G, Murnane JP (June 1999). "Characterization of a human gene with sequence homology to Saccharomyces cerevisiae SIR2".Gene.234 (1):161–168.doi:10.1016/S0378-1119(99)00162-6.PMID10393250.
^Frye RA (June 1999). "Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity".Biochemical and Biophysical Research Communications.260 (1):273–279.doi:10.1006/bbrc.1999.0897.PMID10381378.
^Suzuki T, Khan MN, Sawada H, Imai E, Itoh Y, Yamatsuta K, et al. (June 2012). "Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors".Journal of Medicinal Chemistry.55 (12):5760–5773.doi:10.1021/jm3002108.PMID22642300.
^Gomes P, Fleming Outeiro T, Cavadas C (November 2015). "Emerging Role of Sirtuin 2 in the Regulation of Mammalian Metabolism".Trends in Pharmacological Sciences.36 (11):756–768.doi:10.1016/j.tips.2015.08.001.PMID26538315.
^Inoue T, Hiratsuka M, Osaki M, Yamada H, Kishimoto I, Yamaguchi S, et al. (February 2007). "SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress".Oncogene.26 (7):945–957.doi:10.1038/sj.onc.1209857.PMID16909107.S2CID21357335.
^Han Y, Jin YH, Kim YJ, Kang BY, Choi HJ, Kim DW, et al. (October 2008). "Acetylation of Sirt2 by p300 attenuates its deacetylase activity".Biochemical and Biophysical Research Communications.375 (4):576–580.doi:10.1016/j.bbrc.2008.08.042.PMID18722353.
^Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY, Yeo CY, et al. (April 2008). "Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53".Biochemical and Biophysical Research Communications.368 (3):690–695.doi:10.1016/j.bbrc.2008.01.114.PMID18249187.
Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides".Gene.138 (1–2):171–174.doi:10.1016/0378-1119(94)90802-8.PMID8125298.
Andersson B, Wentland MA, Ricafrente JY, Liu W, Gibbs RA (April 1996). "A "double adaptor" method for improved shotgun library construction".Analytical Biochemistry.236 (1):107–113.doi:10.1006/abio.1996.0138.PMID8619474.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library".Gene.200 (1–2):149–156.doi:10.1016/S0378-1119(97)00411-3.PMID9373149.
Frye RA (July 2000). "Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins".Biochemical and Biophysical Research Communications.273 (2):793–798.doi:10.1006/bbrc.2000.3000.PMID10873683.
De Smet C, Nishimori H, Furnari FB, Bögler O, Huang HJ, Cavenee WK (May 2002). "A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression".Journal of Neurochemistry.81 (3):575–588.doi:10.1046/j.1471-4159.2002.00847.x.PMID12065666.S2CID23925334.
Hiratsuka M, Inoue T, Toda T, Kimura N, Shirayoshi Y, Kamitani H, et al. (September 2003). "Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene".Biochemical and Biophysical Research Communications.309 (3):558–566.doi:10.1016/j.bbrc.2003.08.029.PMID12963026.
Bae NS, Swanson MJ, Vassilev A, Howard BH (June 2004). "Human histone deacetylase SIRT2 interacts with the homeobox transcription factor HOXA10".Journal of Biochemistry.135 (6):695–700.doi:10.1093/jb/mvh084.PMID15213244.
This article incorporates text from this source, which is available under theCC BY 4.0 license.
